Key facts
- Azalea Therapeutics’s last known valuation is $153.0M (Oct 2025).
- It has raised $82.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($65.0M) in Oct 2025.
- Notable investors include RA Capital Management, University of California, Sozo Ventures, Third Rock Ventures, Berkeley — 6 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Azalea Therapeutics
Funding rounds
1 roundsAbout Azalea Therapeutics
Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment. The company offers an Enveloped Delivery Vehicle technology that directs CRISPR-Cas9 cargo to specific cells, enabling patients with cancer, autoimmune, and genetic conditions to receive targeted and sustained therapies.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2023
- Website
- azaleatx.com/
- Ownership
- Privately Held (backing)
Azalea Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Azalea Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Azalea Therapeutics in its N-PORT filings yet. We sweep new filings monthly.